Gilead Sciences Inc. (which shares I currently own) will likely buy Forty Seven Inc. for c. 4.9 bn USD* or $ 95.50 per Share, representing a premium of 96% to the Thursday closing price.
Forty Seven is active in researching cancer treatments that make use of the immune system against tumors.
*) including some other instruments than cash
2 thoughts on “News📰: Gilead Buys Forty Seven for $ 4.9 bn”